arrow
N

Navin Khattry

Tata Memorial Hospital
H指数:22
被引数:1,881

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Defining alteration in bone marrow mesenchymal stem cells (MSC) from acute myeloid leukemia and exploring cultured MSC-conditioned media as a novel anti-leukemia therapy agent

定义急性髓系白血病中骨髓间充质干细胞(MSC)的异常改变,并探讨培养的MSC条件培养基作为新型抗白血病治疗剂的应用。

2026-02-230
OAAI
Is Less “Sufficient” and “Safe” in the MRD Era - Outcomes of Autologous Stem-Cell Transplant as per Melphalan Dose in Patients with Multiple Myeloma

在微小残留病时代,更少的剂量是否“足够”且“安全”?——根据美法仑剂量评估多发性骨髓瘤患者自体干细胞移植的结局

2026-01-080
OAAI
Real World Data on Demographics, Management and Outcome of Ultra High-Risk Myeloma - Experience from a Tertiary Care Centre

超高危骨髓瘤的人口统计学、治疗和结局的真实世界数据——来自一家三级护理中心的经验

2026-01-010
PRE
Multiple Myeloma in Young Adults-Insights From a Tertiary Care Cancer Centre in India

青年多发性骨髓瘤——来自印度一家三级护理癌症中心的研究见解

2025-12-010
OAAI
Treatment free remission (TFR) in chronic myeloid leukemia—results, compliance and patterns of failure from a tertiary care cancer centre in India

慢性髓性白血病中的无治疗缓解(TFR)——来自印度一家三级护理癌症中心的结果、依从性及失败模式

2025-10-310
OA
Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib study (vol 15, 75, 2025)

新型人源化CD19-CAR-T(现名为talicabtagene autoleucel,Tali-cel™)细胞在复发/难治性儿童B急性淋巴细胞白血病中的应用——一项开放标签单臂I/Ib期研究(卷15,第75期,2025年)

2025-05-200
OA
Circulating tumor plasma cells and peripheral blood measurable residual disease assessment in multiple myeloma patients not planned for upfront transplant
2024-04-010
OAAI
Long-Term Cryopreservation of Peripheral Blood Stem Cell Harvest Using Low Concentration (4.35%) Dimethyl Sulfoxide with Methyl Cellulose and Uncontrolled Rate Freezing at-80 °C: An Effective Option in Resource-Limited Settings
2023-12-011
PRE
P454: ACUTE MYELOID LEUKEMIA (AML) WITH IDH1 AND IDH2 MUTATIONS CAN BE EFFECTIVELY RISK STRATIFIED BASED ON THE PRESENCE ADVERSE RISK GENOMIC FEATURES.

P454: 具有IDH1和IDH2突变的急性髓系白血病(AML)可根据不良风险基因组特征的存在进行有效风险分层。

2023-01-010
OA
Comprehensive immune cell profiling depicts an early immune response associated with severe coronavirus disease 2019 in cancer patients
2021-10-278
OAAI